Skip to main content
. 2023 Feb 2;13:1130852. doi: 10.3389/fonc.2023.1130852

Figure 3.

Figure 3

In vitro drug response assays. (A, B) Viability of 2D cells after in vitro treatment with increasing concentrations of Bortezomib (A) or Pevonedistat (B) for 72h. C, (D) Viability of 3D organoids after in vitro treatment with increasing concentrations of Bortezomib (C) or Pevonedistat (D) for 1 week. Cell viability was evaluated using the CellTiter-Glo® assay.